119 related articles for article (PubMed ID: 24408395)
1. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.
Ouellet D; Gibiansky E; Leonowens C; O'Hagan A; Haney P; Switzky J; Goodman VL
J Clin Pharmacol; 2014 Jun; 54(6):696-706. PubMed ID: 24408395
[TBL] [Abstract][Full Text] [Related]
2. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.
Ouellet D; Grossmann KF; Limentani G; Nebot N; Lan K; Knowles L; Gordon MS; Sharma S; Infante JR; Lorusso PM; Pande G; Krachey EC; Blackman SC; Carson SW
J Pharm Sci; 2013 Sep; 102(9):3100-9. PubMed ID: 23608920
[TBL] [Abstract][Full Text] [Related]
3. Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
Denton CL; Minthorn E; Carson SW; Young GC; Richards-Peterson LE; Botbyl J; Han C; Morrison RA; Blackman SC; Ouellet D
J Clin Pharmacol; 2013 Sep; 53(9):955-61. PubMed ID: 23846776
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Suttle AB; Grossmann KF; Ouellet D; Richards-Peterson LE; Aktan G; Gordon MS; LoRusso PM; Infante JR; Sharma S; Kendra K; Patel M; Pant S; Arkenau HT; Middleton MR; Blackman SC; Botbyl J; Carson SW
J Clin Pharmacol; 2015 Apr; 55(4):392-400. PubMed ID: 25449654
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Nebot N; Arkenau HT; Infante JR; Chandler JC; Weickhardt A; Lickliter JD; Sarantopoulos J; Gordon MS; Mak G; St-Pierre A; Tang L; Mookerjee B; Carson SW; Hayes S; Grossmann KF
Br J Clin Pharmacol; 2018 Apr; 84(4):764-775. PubMed ID: 29243287
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A; Noé G; Bellesoeur A; Kramkimel N; Paludetto MN; Thomas-Schoemann A; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Clin Pharmacokinet; 2019 Apr; 58(4):451-467. PubMed ID: 30094711
[TBL] [Abstract][Full Text] [Related]
7. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).
Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau HT; Brown MP; Hamid O; Infante JR; Millward M; Pavlick A; Chin MT; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
Clin Cancer Res; 2014 Sep; 20(17):4449-58. PubMed ID: 24958809
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.
Rowland A; van Dyk M; Hopkins AM; Mounzer R; Polasek TM; Rostami-Hodjegan A; Sorich MJ
Clin Pharmacol Ther; 2018 Dec; 104(6):1219-1228. PubMed ID: 29574693
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Planchard D; Kim TM; Mazieres J; Quoix E; Riely G; Barlesi F; Souquet PJ; Smit EF; Groen HJ; Kelly RJ; Cho BC; Socinski MA; Pandite L; Nase C; Ma B; D'Amelio A; Mookerjee B; Curtis CM; Johnson BE
Lancet Oncol; 2016 May; 17(5):642-50. PubMed ID: 27080216
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
13. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
14. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
Lawrence SK; Nguyen D; Bowen C; Richards-Peterson L; Skordos KW
Drug Metab Dispos; 2014 Jul; 42(7):1180-90. PubMed ID: 24748562
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.
Ouellet D; Kassir N; Chiu J; Mouksassi MS; Leonowens C; Cox D; DeMarini DJ; Gardner O; Crist W; Patel K
Cancer Chemother Pharmacol; 2016 Apr; 77(4):807-17. PubMed ID: 26940938
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
Bershas DA; Ouellet D; Mamaril-Fishman DB; Nebot N; Carson SW; Blackman SC; Morrison RA; Adams JL; Jurusik KE; Knecht DM; Gorycki PD; Richards-Peterson LE
Drug Metab Dispos; 2013 Dec; 41(12):2215-24. PubMed ID: 24097902
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():124-8. PubMed ID: 23537694
[TBL] [Abstract][Full Text] [Related]
19. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]